trump glp 1 executive order targets high drug prices with new Trump signs directive on lowering

Moreover, differences in outcome reporting, such as the use of absolute versus relative changes, or inconsistent definitions of endpoints like visceral adiposity or insulin resistance, further limited the ability to standardize data extraction and synthesis

(2023) from Food and Drug Administration (FDA)

In SURMOUNT-1, a study in 2,539 adults with obesity, or excess weight and weight-related medical problems not including diabetes, people taking Zepbound as an adjunct to diet and exercise experienced substantial weight loss compared with placebo at 72 weeks

[DOI] [PubMed] [Google Scholar] 4

Like GLP-1 itself, and like an earlier drug, liraglutide, that was approved in 2010, it suppresses the release of glucagon a hormone secreted by the pancreas to raise blood sugar levels